Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma

Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma

(2011) Peter C. Trask et al.   Journal of Cancer Survivorship

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma

(2010) S. Patil et al.   ANNALS OF ONCOLOGY

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis

(2010) D Cella et al.   BRITISH JOURNAL OF CANCER

Treatment of metastatic renal cell carcinoma

(2010) Maxine Sun et al.   Nature Reviews Urology

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa

(2009) David Cella et al.   Journal of Oncology Practice

Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial

(2008) David Cella et al.   JOURNAL OF CLINICAL ONCOLOGY